| Budget Amount *help |
¥2,900,000 (Direct Cost: ¥2,900,000)
Fiscal Year 2003: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2002: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Research Abstract |
In the present study, we have investigated in order to identify predictive factors for docetaxel (DOC) in breast cancers. Thirty-nine patients with locally advanced breast tumors or locally recurrent tumors underwent tumor biopsy and were treated with DOC. The expression levels of CYP3A4, class I, class III β-tubulin~ BRCA1, BRCA2 mRNA were identified by a real-time PCR assay. In addition, the expression level of P-gp, p53, and BCL-2 analyzed by immunohistochemical staining was compared with response to DOC. Response rate to DOC in high expression group of CYP3A4, class I, class III 6-tubulin, and BRCA2 was significantly lower than that in low expression group. On the contrary, there was no significant association of the expression level of BRCA1, P-gp, p53, and BCL-2 with response to DOC. These results suggest that intratumoral expression level of CYP3A4, class I, class III β-tubulin, and BRCA2 mRNA would be clinically useful in the prediction of response to DOC treatment in breast cancer patients.
|
